Xilio Therapeutics Immuno-Oncology 2024 Investor Presentation

Xilio Therapeutics presents clinical development updates on three immuno-oncology programs: XTX101 (CTLA-4) in combination with atezolizumab for microsatellite-stable colorectal cancer, XTX202 (IL-2βγ) for melanoma and renal cell carcinoma, and XTX301 (IL-12) for solid tumors. The company outlines anticipated 2024 clinical milestones and $50-75M capital raise to support program advancement.